Drilling Addendum to Resource Assessment of Low- and Moderate-Temperature Geothermal Waters in Calistoga, Napa County, California

This addendum report presents the results of the California Division of Mines and Geology (CDMG) drilling program at Calistoga, California, which was the final geothermal-resource assessment investigation performed under terms of the second year contract (1979-80) between the U.S. Department of Energy (DOE) and the CDMG under the State Coupled Program. This report is intended to supplement information presented in CDMG's technical report for the project year, ''Resource Assessment of Low- and Moderate-Temperature Geothermal Waters in Calistoga, Napa County, California''. During the investigative phase of the CDMG's Geothermal Project, over 200 well-driller's reports were obtained from the Department of Water Resources (DWR). It was hoped that the interpretation and correlation of these logs would reveal the subsurface geology of the Upper Napa Valley and also provide a check for the various geophysical surveys that were performed in the course of the study. However, these DWR driller logs proved to be inadequate due to the brief, non-technical, and erroneous descriptions contained on the logs. As a result of the lack of useable drill-hole data, and because information was desired from,deeper horizons, it became evident that drilling some exploratory holes would be necessary in order to obtain physical evidence of the stratigraphy and aquifers in the immediate Calistoga area. Pursuant to this objective, a total of twelve sites were selected--four under jurisdiction of Napa County and eight under jurisdiction of the City of Calistoga. A moratorium is currently in existence within Napa County on most geothermal drilling, and environmental and time constraints precluded CDMG from obtaining the necessary site permits within the county. However, a variance was applied for and obtained from the City of Calistoga to allow CDMG to drill within the city limits. With this areal constraint and also funding limits in mind, six drilling sites were selected on the basis of (1) proximity to areas where geophysical surveys had been performed, (2) accessibility of the site for drill rig setup, and (3) favorability for obtaining the maximum information possible concerning the geology and the resources. Necessary landowner permission and permits were secured for these sites, and actual drilling began on December 17, 1980. Drilling was terminated on February 4, 1981, with the completion of three holes that ranged in depth from 205 to 885 feet. Use of a relatively new drilling technique called the Dual Tube Method enabled the collection of precise subsurface data of a level of detail never before obtained in the Calistoga area. As a result, a totally new and unexpected picture of the geothermal reservoir conditions there has been obtained, and is outlined in this addendum report

Investigation of Low-Temperature Geothermal Resources in the Sonoma Valley Area, California

The Sonoma Valley area contains low-temperature geothermal resources (20 C {le} T {le} 90 C) having the potential for useful development. Sonoma Valley residents, local governments and institutions, private developers, and manufacturers may be able to utilize the geothermal resources as an alternate energy source. Historically, there have been at least six geothermal spring areas developed in the Sonoma Valley. Four of these (Boyes Hot Springs, Fetter's Hot Springs, Agua Caliente Springs, and the Sonoma State Hospital warm spring) lie on a linear trend extending northwestward from the City of Sonoma. Detailed geophysical surveys delineated a major fault trace along the east side of the Sonoma Valley in association with the historic geothermal areas. Other fault traces were also delineated revealing a general northwest-trending structural faulting fabric underlying the valley. Water wells located near the ''east side'' fault have relatively high boron concentrations. Geochemical evidence may suggest the ''east side'' fault presents a barrier to lateral fluid migration but is a conduit for ascending fluids. Fifteen of the twenty-nine geothermal wells or springs located from literature research or field surveys are located along or east of this major fault in a 10 km (6.2 miles) long, narrow zone. The highest recorded water temperature in the valley appears to be 62.7 C (145 F) at 137.2 meters (450 feet) in a well at Boyes Hot Springs. This is consistent with the geothermal reservoir temperature range of 52-77 C (126-171 F) indicated by geothermometry calculations performed on data from wells in the area. Interpretation of data indicates a low-temperature geothermal fluid upwelling or ''plume'', along the ''east side'' fault with subsequent migration into permeable aquifers predominantly within volcanic strata. It is quite likely other geothermal fluid ''plumes'' in association with faulting are present within the Sonoma Valley area. A 5.8 km{sup 2} geothermal zone, that parallels the fault trace, is delineated and is perhaps the most favorable area for further investigation and possible geothermal production

Commentaries on viewpoint : physiology and fast marathons

Q2Q1N/

COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing

Background Lateral flow device (LFD) viral antigen immunoassays have been developed around the world as diagnostic tests for SARS-CoV-2 infection. They have been proposed to deliver an infrastructure-light, cost-economical solution giving results within half an hour. Methods LFDs were initially reviewed by a Department of Health and Social Care team, part of the UK government, from which 64 were selected for further evaluation from 1st August to 15th December 2020. Standardised laboratory evaluations, and for those that met the published criteria, field testing in the Falcon-C19 research study and UK pilots were performed (UK COVID-19 testing centres, hospital, schools, armed forces). Findings 4/64 LFDs so far have desirable performance characteristics (orient Gene, Deepblue, Abbott and Innova SARS-CoV-2 Antigen Rapid Qualitative Test). All these LFDs have a viral antigen detection of >90% at 100,000 RNA copies/ml. 8951 Innova LFD tests were performed with a kit failure rate of 5.6% (502/8951, 95% CI: 5.1–6.1), false positive rate of 0.32% (22/6954, 95% CI: 0.20–0.48). Viral antigen detection/sensitivity across the sampling cohort when performed by laboratory scientists was 78.8% (156/198, 95% CI 72.4–84.3). Interpretation Our results suggest LFDs have promising performance characteristics for mass population testing and can be used to identify infectious positive individuals. The Innova LFD shows good viral antigen detection/sensitivity with excellent specificity, although kit failure rates and the impact of training are potential issues. These results support the expanded evaluation of LFDs, and assessment of greater access to testing on COVID-19 transmission. Funding Department of Health and Social Care. University of Oxford. Public Health England Porton Down, Manchester University NHS Foundation Trust, National Institute of Health Research

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Background The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19. Funding PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care. COVIDENCE UK is supported by the UK Research and Innovation, the National Institute for Health Research, and Barts Charity. The views expressed are those of the authors and not necessarily those of the funders

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

Background No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge. Methods The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing. Findings 2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7–9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46–0·99]), obesity (0·50 [0·34–0·74]) and invasive mechanical ventilation (0·42 [0·23–0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74–1·00]), at 5 months (0·74 [0·64–0·88]) to 1 year (0·75 [0·62–0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters. Interpretation The sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials. Funding UK Research and Innovation and National Institute for Health Research